• AXIM Biotechnologies (OTCQB:AXIM) announces the start of clinical trials for ImmunoPass, the company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19.
  • Measuring neutralizing antibodies in people after vaccination may give a better look at how COVID-19 vaccine responses hold up over time.
  • AXIM’s ImmunoPass has shown a significantly better statistical correlation with SARS-CoV-2 neutralization assays than the currently available antibody tests, the company said.
  • The test is based on blocking the interaction between human cell receptors and the viral spike protein that mimics the virus neutralization process in the body.